hydroxychloroquine has been researched along with Premature Birth in 33 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Premature Birth: CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 9.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 9.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 8.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| "Among pregnancies exposed to 4-aminoquinolines (chloroquine and HCQ), no increased risk of major birth defects, preterm birth, or SGA was identified." | 8.02 | Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. ( Andersen, JT; Andersson, NW; Skov, L, 2021) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 7.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 7.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "A total of 40 infants born from mothers affected by rheumatic diseases and treated with hydroxychloroquine during pregnancy were enrolled in a prospective observational study." | 7.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 5.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| " The HCQ group showed a trend towards lower dosage of prednisone (OR 0." | 5.46 | Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. ( de Hair, MJH; Derksen, RHWM; Fritsch-Stork, RDE; Kroese, SJ; Lely, AT; Limper, M; van Laar, JM, 2017) |
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 5.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy." | 5.12 | Hydroxychloroquine in lupus pregnancy. ( Clowse, ME; Magder, L; Petri, M; Witter, F, 2006) |
| " Hydroxychloroquine (HCQ) appears protective against flares in pregnancy, neonatal congenital heart block and preterm birth." | 5.01 | Systemic lupus erythematosus in pregnancy: high risk, high reward. ( Do, SC; Druzin, ML, 2019) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 4.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| "Findings from previous small studies have been reassuring regarding the safety of treatment with hydroxychloroquine (HCQ) during pregnancy." | 4.12 | Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study. ( Adam, MP; Braddock, SR; Burke, L; Chambers, CD; Felix, R; Fine, M; Johnson, DL; Jones, KL; Lessard, C; Luo, Y; Robinson, LK; Xu, R, 2022) |
| "Evaluate the impact of pregnancy physiology and medication non-adherence on serum hydroxychloroquine (HCQ) pharmacokinetics (PK) and exposure-response in SLE." | 4.12 | Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Gonzalez, D; Hornik, CP; Maharaj, AR; Weiner, D, 2022) |
| "Among pregnancies exposed to 4-aminoquinolines (chloroquine and HCQ), no increased risk of major birth defects, preterm birth, or SGA was identified." | 4.02 | Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. ( Andersen, JT; Andersson, NW; Skov, L, 2021) |
| " Several management options for prolongation of pregnancy such as plasma exchange, pravastatin, LMHW, hydroxychloroquine/HCQ, or TNF-alpha blocker should be discussed with the patients." | 3.96 | Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases. ( Cervar-Zivkovic, M; Mayer-Pickel, K; Moertl, M; Schöll, W; Stern, C, 2020) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 3.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 3.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "A total of 40 infants born from mothers affected by rheumatic diseases and treated with hydroxychloroquine during pregnancy were enrolled in a prospective observational study." | 3.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| "Pregnancy was formerly discouraged in patients with SLE because of unstable disease activity during the gestation period, increased thrombosis risk, severe organ damage, and inevitable side effects of immunosuppressive agents." | 2.82 | Pregnancy-related complications in systemic lupus erythematosus. ( Cui, L; Li, Z; Liu, Q; Mu, R; Qiao, J; Tan, Y; Yang, S, 2022) |
| "In the 1980's, pregnancies in systemic sclerosis (SSc) patients were considered to be at high risk for poor foetal and maternal outcome." | 2.44 | [Pregnancy in systemic sclerosis]. ( Bérezné, A; Mouthon, L, 2008) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 1.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| "A history of lupus nephritis was noted in 29/121 (24%) patients." | 1.56 | Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists. ( Bhat, V; Haridas, V; Janardana, R; Jois, R; Pinto, B; Priya, V; Rao, VK; Shobha, V; Singh, Y; Srikantiah, C, 2020) |
| "Hydroxychloroquine was used to treat both patients; the first patient was treated with it over a period of 14 days before showing signs of improvement." | 1.56 | Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report. ( Atef-Yekta, R; Jafary, M; Lamsehchi, A; Sadeghi, K; Sagheb, S, 2020) |
| "Preterm birth was defined as a birth <37 weeks gestation." | 1.48 | Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. ( Clowse, MEB; Eudy, AM; Haroun, T; James, AH; Jayasundara, M; Neil, L, 2018) |
| " The HCQ group showed a trend towards lower dosage of prednisone (OR 0." | 1.46 | Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. ( de Hair, MJH; Derksen, RHWM; Fritsch-Stork, RDE; Kroese, SJ; Lely, AT; Limper, M; van Laar, JM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (12.12) | 29.6817 |
| 2010's | 12 (36.36) | 24.3611 |
| 2020's | 17 (51.52) | 2.80 |
| Authors | Studies |
|---|---|
| Chambers, CD | 1 |
| Johnson, DL | 1 |
| Xu, R | 1 |
| Luo, Y | 1 |
| Felix, R | 1 |
| Fine, M | 1 |
| Lessard, C | 1 |
| Adam, MP | 1 |
| Braddock, SR | 1 |
| Robinson, LK | 1 |
| Burke, L | 1 |
| Jones, KL | 1 |
| Balevic, SJ | 1 |
| Weiner, D | 1 |
| Clowse, MEB | 2 |
| Eudy, AM | 2 |
| Maharaj, AR | 1 |
| Hornik, CP | 1 |
| Cohen-Wolkowiez, M | 1 |
| Gonzalez, D | 1 |
| Reynolds, JA | 1 |
| Gayed, M | 1 |
| Khamashta, MA | 1 |
| Leone, F | 1 |
| Toescu, V | 1 |
| Bruce, IN | 1 |
| Giles, I | 1 |
| Teh, LS | 1 |
| McHugh, N | 1 |
| Akil, M | 1 |
| Edwards, CJ | 1 |
| Gordon, C | 1 |
| Tan, Y | 1 |
| Yang, S | 1 |
| Liu, Q | 1 |
| Li, Z | 1 |
| Mu, R | 1 |
| Qiao, J | 1 |
| Cui, L | 1 |
| Liu, Y | 2 |
| Wei, Y | 2 |
| Zhang, Y | 2 |
| Yang, H | 2 |
| Petri, M | 3 |
| Do, SC | 2 |
| Rizk, NM | 1 |
| Druzin, ML | 3 |
| Simard, JF | 1 |
| Mayer-Pickel, K | 1 |
| Stern, C | 1 |
| Cervar-Zivkovic, M | 1 |
| Schöll, W | 1 |
| Moertl, M | 1 |
| Janardana, R | 1 |
| Haridas, V | 1 |
| Priya, V | 1 |
| Bhat, V | 1 |
| Singh, Y | 1 |
| Rao, VK | 1 |
| Jois, R | 1 |
| Srikantiah, C | 1 |
| Pinto, B | 1 |
| Shobha, V | 1 |
| Sagheb, S | 1 |
| Lamsehchi, A | 1 |
| Jafary, M | 1 |
| Atef-Yekta, R | 1 |
| Sadeghi, K | 1 |
| Di Mascio, D | 1 |
| D'Antonio, F | 1 |
| Beksac, MS | 1 |
| Donmez, HG | 1 |
| Hammad, I | 1 |
| Porter, TF | 1 |
| Andersson, NW | 1 |
| Skov, L | 1 |
| Andersen, JT | 1 |
| Ortiz Molina, E | 1 |
| Hernandez Pailos, R | 1 |
| Pola Guillen, M | 1 |
| Pascual Pedreno, A | 1 |
| Rodriguez Rodriguez, E | 1 |
| Hernandez Martinez, A | 1 |
| Dubey, P | 1 |
| Thakur, B | 1 |
| Reddy, S | 1 |
| Martinez, CA | 1 |
| Nurunnabi, M | 1 |
| Manuel, SL | 1 |
| Chheda, S | 1 |
| Bracamontes, C | 1 |
| Dwivedi, AK | 1 |
| Lateef, A | 1 |
| Jayasundara, M | 1 |
| Haroun, T | 1 |
| Neil, L | 1 |
| James, AH | 1 |
| Kroese, SJ | 1 |
| de Hair, MJH | 1 |
| Limper, M | 1 |
| Lely, AT | 1 |
| van Laar, JM | 1 |
| Derksen, RHWM | 1 |
| Fritsch-Stork, RDE | 1 |
| Guillotin, V | 1 |
| Bouhet, A | 1 |
| Barnetche, T | 1 |
| Richez, C | 1 |
| Truchetet, ME | 1 |
| Seneschal, J | 1 |
| Duffau, P | 1 |
| Lazaro, E | 2 |
| Chehab, G | 1 |
| Krüssel, J | 1 |
| Fehm, T | 1 |
| Fischer-Betz, R | 1 |
| Schneider, M | 1 |
| Germeyer, A | 1 |
| Suerdieck, MB | 1 |
| Kreuzer, V | 1 |
| Liebenthron, J | 1 |
| Seo, MR | 1 |
| Chae, J | 1 |
| Kim, YM | 1 |
| Cha, HS | 1 |
| Choi, SJ | 1 |
| Oh, S | 1 |
| Roh, CR | 1 |
| Koh, JH | 1 |
| Ko, HS | 1 |
| Kwok, SK | 1 |
| Ju, JH | 1 |
| Park, SH | 1 |
| Leroux, M | 1 |
| Desveaux, C | 1 |
| Parcevaux, M | 1 |
| Julliac, B | 1 |
| Gouyon, JB | 1 |
| Dallay, D | 1 |
| Pellegrin, JL | 1 |
| Boukerrou, M | 1 |
| Blanco, P | 1 |
| Kaplan, YC | 1 |
| Ozsarfati, J | 1 |
| Nickel, C | 1 |
| Koren, G | 1 |
| Schreiber, K | 1 |
| Hunt, BJ | 1 |
| Bérezné, A | 1 |
| Mouthon, L | 1 |
| Iba-Ba, J | 1 |
| Mayi-Tsonga, S | 1 |
| Ibouili Bignoumba, R | 1 |
| Diallo, T | 1 |
| Moussavou Kombila, JB | 1 |
| Coniquet, S | 1 |
| Mihindou Boussougou, C | 1 |
| Boguikouma, JB | 1 |
| Langen, ES | 1 |
| Chakravarty, EF | 1 |
| Liaquat, M | 1 |
| El-Sayed, YY | 1 |
| Motta, M | 1 |
| Tincani, A | 1 |
| Faden, D | 1 |
| Zinzini, E | 1 |
| Lojacono, A | 1 |
| Marchesi, A | 1 |
| Frassi, M | 1 |
| Biasini, C | 1 |
| Zatti, S | 1 |
| Chirico, G | 1 |
| Clowse, ME | 1 |
| Magder, L | 1 |
| Witter, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for hydroxychloroquine and Premature Birth
| Article | Year |
|---|---|
Pregnancy-related complications in systemic lupus erythematosus.
Topics: Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Systemic; Pregnancy; Pregn | 2022 |
Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis.
Topics: Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; Hypertension, Pregnan | 2023 |
Pregnancy and Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newborn | 2020 |
Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
An Update on Biologic Agents During Pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humani | 2020 |
Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Asia; Cesarean Section; COVID-19; COVID-19 Drug Trea | 2021 |
Systemic Lupus Erythematosus and Pregnancy.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychlo | 2017 |
Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis.
Topics: Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Infant, Newborn; | 2018 |
Systemic lupus erythematosus in pregnancy: high risk, high reward.
Topics: Adult; Counseling; Female; Fetal Growth Retardation; Humans; Hydroxychloroquine; Lupus Erythematosus | 2019 |
Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Autoimmune Diseases; Female; Humans; Hydroxychloroquine | 2016 |
Pregnancy and Antiphospholipid Syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Fetal Growth Retardation; Humans; H | 2016 |
[Pregnancy in systemic sclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Female; Fetal Diseases; Humans; Hydr | 2008 |
1 trial available for hydroxychloroquine and Premature Birth
| Article | Year |
|---|---|
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
Hydroxychloroquine in lupus pregnancy.
Topics: Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2006 |
20 other studies available for hydroxychloroquine and Premature Birth
| Article | Year |
|---|---|
Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study.
Topics: Abortion, Spontaneous; Cohort Studies; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; | 2022 |
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine.
Topics: Adolescent; Antirheumatic Agents; Azathioprine; Child; Female; Humans; Hydroxychloroquine; Lupus Ery | 2023 |
Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies?
Topics: Adult; Antirheumatic Agents; California; Female; Humans; Hydroxychloroquine; Logistic Models; Lupus | 2020 |
Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases.
Topics: Adult; Antiphospholipid Syndrome; Female; Fetal Viability; Gestational Age; Heparin, Low-Molecular-W | 2020 |
Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hydroxychloroquine; India; Infant, Newborn; Lupus Eryt | 2020 |
Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report.
Topics: Adult; Antiviral Agents; Betacoronavirus; Blood Chemical Analysis; Coronavirus Infections; COVID-19; | 2020 |
Perinatal mortality and morbidity of SARS-COV-2 infection during pregnancy in European countries: Findings from an international study.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Asia; Asymptomatic Infections; Austr | 2021 |
Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Immune System; Infant, Newborn; Pharmaceut | 2021 |
Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Cohort Studies; Denmark; Female; Humans; Hydroxychlor | 2021 |
COVID-19 infection in symptomatic pregnant women at the midpoint of the pandemic in Spain: a retrospective analysis.
Topics: Adult; Anosmia; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; C-Reactive Protein; Cesarea | 2020 |
Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cesarean Section; Female; Ges | 2018 |
Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infan | 2017 |
Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Cryopreservation; Cyclophosphamide; Female; | 2019 |
Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Infant, Newborn; L | 2019 |
Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Apgar Score; Female; Fetal Growth Retardation; Follow-Up Studies; Human | 2015 |
Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Gluc | 2015 |
[Dermatomyositis and pregnancy: a case in Gabon].
Topics: Adult; Antirheumatic Agents; Cesarean Section; Dermatomyositis; Female; Gabon; Glucocorticoids; Huma | 2009 |
High rate of preterm birth in pregnancies complicated by rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Congenital Abnormalities; Female; Fetal Distress | 2014 |
Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation.
Topics: Antirheumatic Agents; Breast Feeding; Child Development; Female; Follow-Up Studies; Humans; Hydroxyc | 2005 |